Pralatrexate for refractory mycosis fungoides in two Japanese patients

Pralatrexate has been approved for the treatment of relapsed/refractory peripheral T cell lymphomas. Studies in the U.S. also support the clinical efficacy of pralatrexate to treat advanced‐stage cutaneous T‐cell lymphomas, but outcomes in Japanese patients have not yet been reported. We herein describe two Japanese patients with heavily‐pretreated relapsed/refractory mycosis fungoides that were successfully controlled by pralatrexate.

[1]  K. Kitazume,et al.  Pralatrexate for Prolonged Treatment of Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, with Prophylactic Leucovorin , 2019, Case Reports in Oncology.

[2]  Anlong Li,et al.  Clinical Activity of Pralatrexate in Patients With Cutaneous T‐Cell Lymphoma Treated With Varying Doses of Pralatrexate , 2018, Clinical lymphoma, myeloma & leukemia.

[3]  C. McCormack,et al.  Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome , 2018, Current Oncology Reports.

[4]  L. Schwartz,et al.  A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. , 2018, Blood.

[5]  R. Ueda,et al.  Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T‐cell lymphoma , 2017, Cancer science.

[6]  P. Zinzani,et al.  Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma , 2017, Clinical Cancer Research.

[7]  G. Wood,et al.  Methotrexate and Pralatrexate. , 2015, Dermatologic clinics.

[8]  M. Duvic,et al.  Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides. , 2014, Clinical lymphoma, myeloma & leukemia.

[9]  H. Koga,et al.  Guidelines for the management of cutaneous lymphomas (2011): A consensus statement by the Japanese Skin Cancer Society – Lymphoma Study Group , 2013, The Journal of dermatology.

[10]  B. Coiffier,et al.  Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study. , 2012, Clinical lymphoma, myeloma & leukemia.

[11]  K. Savage,et al.  Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Fisher,et al.  Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study. , 2010 .

[13]  J. Scarisbrick,et al.  Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Zelenetz,et al.  Activity of a Novel Anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against Human Lymphoma is Superior to Methotrexate and Correlates with Tumor RFC-1 Gene Expression , 2003, Leukemia & lymphoma.